ArticleCurrent oncology (Toronto, Ont.)2024

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Anna-Maria Lazaratos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.